Predictive tools will seek to reduce leading cause of failure rates in clinical trials of oncology drugs.

预测工具将寻求降低肿瘤药物临床试验失败率的主要原因。

Integrated AI and microscopy expected to lead to better understanding of tumor structures and treatment strategies.

综合AI和显微镜有望更好地了解肿瘤结构和治疗策略。

New technology will work to capture and analyze the highly heterogeneous tumor microenvironment.

新技术将致力于捕获和分析高度异质的肿瘤微环境。

WASHINGTON, July 11, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, today launched a research collaboration with Stanford University's Department of Bioengineering intended to shape the future of cancer drug screening through 'smart microscopy.' Combining spatial biology with artificial intelligence (AI), the research team at the Danaher Beacon for Spatialomics aims to help de-risk cancer drug development..

华盛顿，2024年7月11日/PRNewswire/--全球科技创新者Danaher Corporation（纽约证券交易所：DHR）今天与斯坦福大学生物工程系启动了一项研究合作，旨在通过“智能显微镜”塑造癌症药物筛查的未来Danaher Beacon for Spatialomics的研究团队将空间生物学与人工智能（AI）相结合，旨在帮助降低癌症药物开发的风险。。

Tumors are highly variable, not just from tumor to tumor but within each tumor itself. This variation in the 'microenvironment' leads to unpredictable clinical outcomes, including high failure rates during clinical trials. The collaboration aims to leverage the latest findings in spatial biology coupled with cutting-edge AI to make it possible to screen more complex cellular systems..

肿瘤是高度可变的，不仅从肿瘤到肿瘤，而且在每个肿瘤本身内。“微环境”的这种变化导致不可预测的临床结果，包括临床试验期间的高失败率。该合作旨在利用空间生物学的最新发现以及尖端人工智能，使筛选更复杂的细胞系统成为可能。。

Chandra Ramanathan, VP and Head of External Innovation of Danaher's DH Life Sciences LLC subsidiary, said: 'Many oncology drug trials fail because we cannot yet capture and analyze the nuances of the tumor microenvironment and how key proteins spatially interact with each other. Addressing this challenge will require collecting data at scale and designing new ways to analyze it.

Danaher的DH Life Sciences LLC子公司副总裁兼外部创新主管Chandra Ramanathan说：“许多肿瘤药物试验失败，因为我们还不能捕捉和分析肿瘤微环境的细微差别以及关键蛋白质在空间上如何相互作用。应对这一挑战需要大规模收集数据并设计新的分析方法。

We are delighted to commit Danaher's expertise to seek to develop AI-driven phenotyping that could improve drug screening and bring more effective and safer drugs to cancer patients.'  .

我们很高兴将Danaher的专业知识用于寻求开发AI驱动的表型分析，这可以改善药物筛选，并为癌症患者带来更有效和更安全的药物。”。

Emma Lundberg, Ph.D., Associate Professor of Bioengineering and Pathology at Stanford University, said: 'We're at the brink of a new era when it comes to spatial biology and structural cell modeling. This research collaboration will seek to apply the latest microscopy and AI tools at the scale needed to understand treatment responses based on differences in protein expression that change across regions of the tumor.'.

斯坦福大学生物工程与病理学副教授艾玛·伦德伯格博士说：“在空间生物学和结构细胞建模方面，我们正处于一个新时代的边缘。这项研究合作将寻求以所需的规模应用最新的显微镜和AI工具，以了解基于跨肿瘤区域变化的蛋白质表达差异的治疗反应。”。

The collaboration is a partnership between Leica Microsystems, a Danaher subsidiary, and Lundberg, a researcher and leader in the field of spatial proteomics and cell biology known for her involvement in the Human Protein Atlas project. The outcome could be an analysis engine that can detect spatial, proteomic, and metabolic changes in the tumor microenvironment and more accurately predict how tumors will respond to potential therapies..

这项合作是Danaher子公司Leica Microsystems与Lundberg之间的合作，Lundberg是空间蛋白质组学和细胞生物学领域的研究人员和领导者，因参与人类蛋白质图谱项目而闻名。结果可能是一个分析引擎，可以检测肿瘤微环境中的空间，蛋白质组学和代谢变化，并更准确地预测肿瘤对潜在疗法的反应。。

The collaboration is the latest addition to the Danaher Beacons program, which funds product-driven scientific research with globally recognized academic investigators.

这项合作是Danaher Beacons项目的最新成果，该项目由全球公认的学术研究人员资助产品驱动的科学研究。

ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world.

关于DANAHER DANAHER是全球领先的生命科学和诊断创新者，致力于加速科学技术的力量，改善人类健康。我们的业务与客户密切合作，以解决影响世界各地患者的许多最重要的健康挑战。

Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow.

Danaher的先进科学技术和经验证的创新能力有助于实现更快，更准确的诊断，并有助于减少持续发现，开发和提供改变生命的疗法所需的时间和成本。专注于科学卓越、创新和持续改进，我们在全球约有63000名员工帮助确保Danaher今天为数十亿人改善生活质量，同时为更健康、更可持续的明天奠定基础。

Explore more at www.danaher.com. .

。

FORWARD-LOOKING STATEMENTS Statements in this release that are not strictly historical, including any statements regarding events or developments that Danaher believes or anticipates will or may occur in the future are 'forward-looking' statements within the meaning of the federal securities laws. These factors include, among other things: unanticipated, further declines in demand for our COVID-19 related products, the impact of global health crises, the impact of our debt obligations on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relat.

前瞻性声明本新闻稿中并非严格历史性的声明，包括Danaher认为或预期未来将或可能发生的任何事件或发展的声明，都是联邦证券法意义上的“前瞻性”声明。除其他因素外，这些因素包括：对新型冠状病毒相关产品的需求意外进一步下降，全球健康危机的影响，我们的债务义务对我们的运营和流动性的影响，全球经济的恶化或不稳定，我们服务的市场和金融市场，我们的业务和产品中人工智能的开发、部署和使用的不确定性，与国家法律或政策有关的不确定性，包括保护或促进国内利益和/或解决我们服务的市场的外国竞争、收缩或增长率和周期性的法律或政策，竞争，我们开发和成功营销新产品和技术并扩展到新市场的能力，我们员工不当行为的可能性，等等。代理人或业务伙伴，。

SOURCE Danaher Corporation

来源：Danaher Corporation